Welcome to our dedicated page for Shockwave Medical news (Ticker: $SWAV), a resource for investors and traders seeking the latest updates and insights on Shockwave Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shockwave Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shockwave Medical's position in the market.
Shockwave Medical, Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $218.8 million, a 36% increase from the same period in 2023. The company's gross profit was $190.6 million, operating expenses rose by 48%, and net income improved to $55.3 million. Adjusted EBITDA increased by 19% to $68.5 million. Shockwave Medical's cash position stood at $1,029.2 million as of March 31, 2024. The company has withdrawn its full year 2024 guidance due to the proposed acquisition by Johnson & Johnson.